⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 1, 2025Zeitschrift für Gastroenterologie

A pharmacokinetic (PK) similarity study between AVT05 and reference product golimumab

Christopher Wynne Ulrike Lorch Edrich Krantz Rohit Katial Thomas Ashdown Steffen Leutz

View at Publisher

Ask AI

Bookmark

Share

Key Points

AVT05 demonstrated pharmacokinetic similarity to golimumab, indicating comparable behavior in the body.
The study evaluated the pharmacokinetics over a specific time period, showing consistent absorption and elimination rates.
Using a comparative method noted for its detail, the research analyzed specific performance metrics to affirm biosimilarity.
These findings support further development efforts, which may lead to expanded treatment options for patients.

Implication

Study shows pharmacokinetic similarity of AVT05 to golimumab, suggesting potential for biosimilarity in treatment.

Abstract

Introduction: AVT05, a recombinant human IgG1κ monoclonal antibody (mAb), is a proposed biosimilar to golimumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wynne et al. (2025) studied this question.

synapsesocial.com/papers/68c193fb9b7b07f3a06184d1 https://doi.org/10.1055/s-0045-1810735

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study2025
2Assessment of comparative efficacy between candidate biosimilar AVT05 and reference golimumab2025 · 1 citations
3Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar <scp>ABP</scp> 501, Adalimumab‐AttoOriginal Research · 2026
4Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA2024
5Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study2024 · 5 citations

More related papers

Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study2026
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh2024
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks2026

More from Zeitschrift für Gastroenterologie

Food impactions in the esophagus: incidence, causes, and treatmentWed,
Endoscopic Ultrasound-Guided Biliary Drainage (EUS-BD) for malignant biliary obstruction after failed endoscopic retrograde cholangiography (ERC) in patients with surgically altered anatomyWed,